The Diastolic Blood Pressure J-Curve in Hypertension Management: Links and Risk for Cardiovascular Disease

References

• Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441–450. doi:10.1161/CIRCULATIONAHA.115.018912
   PubMed Web of Science ®Google Scholar
• Carey RM, Whelton PK. 2017 ACC/AHA Hypertension Guideline Writing Committee. Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline. Ann Intern Med. 2018;168(5):351–358. doi:10.7326/M17-3203
   PubMed Web of Science ®Google Scholar
• Kompaniyets L, Pennington AF, Goodman AB, et al. Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020–March 2021. Prev Chronic Dis. 2021;18:E66. doi:10.5888/pcd18.210123
   PubMed Web of Science ®Google Scholar
• Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021;(ehab484). doi:10.1093/eurheartj/ehab484
   Web of Science ®Google Scholar
• Zhang W, Zhang S, Deng Y, et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021;385:1268–1279. doi:10.1056/NEJMoa2111437
   PubMed Web of Science ®Google Scholar
• SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–2116. doi:10.1056/NEJMoa1511939
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet Lond Engl. 2002;360(9349):1903–1913. doi:10.1016/s0140-6736(02)11911-8
   PubMed Web of Science ®Google Scholar
• Whelton SP, McEvoy JW, Shaw L, et al. Association of normal systolic blood pressure level with cardiovascular disease in the absence of risk factors. JAMA Cardiol. 2020;5(9):1011–1018. doi:10.1001/jamacardio.2020.1731
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104. doi:10.1093/eurheartj/ehy339
   PubMed Web of Science ®Google Scholar
• Cicero AFG, Fogacci F, Borghi C. Cost-effectiveness analysis of different hypertension management strategies. Intern Emerg Med. 2020;15(2):181–182. doi:10.1007/s11739-019-02153-w
   Web of Science ®Google Scholar
• Rahman F, McEvoy JW. The J-shaped curve for blood pressure and cardiovascular disease risk: historical context and recent updates. Curr Atheroscler Rep. 2017;19(8):34. doi:10.1007/s11883-017-0670-1
   Web of Science ®Google Scholar
• Kjeldsen SE, Oparil S, Narkiewicz K, Hedner T. The J-curve phenomenon revisited again: SPRINT outcomes favor target systolic blood pressure below 120 mmHg. Blood Press. 2016;25(1):1–3. doi:10.3109/08037051.2016.1096564
   PubMed Web of Science ®Google Scholar
• Mancia G, Grassi G. Aggressive blood pressure lowering is dangerous: the J-curve: pro side of the argument. Hypertens Dallas Tex. 2014;63(1):29–36. doi:10.1161/01.hyp.0000441190.09494.e9
   Web of Science ®Google Scholar
• Messerli FH, Panjrath GS. The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? J Am Coll Cardiol. 2009;54(20):1827–1834. doi:10.1016/j.jacc.2009.05.073
   Web of Science ®Google Scholar
• Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet Lond Engl. 2016;387(10022):957–967. doi:10.1016/S0140-6736(15)01225-8
   PubMed Web of Science ®Google Scholar
• Böhm M, Schumacher H, Teo KK, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017;389(10085):2226–2237. doi:10.1016/S0140-6736(17)30754-7
   PubMed Web of Science ®Google Scholar
• Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet Lond Engl. 1987;329(8533):581–584. doi:10.1016/s0140-6736(87)90231-5
   Google Scholar
• Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? JAMA. 1991;265(4):489–495. doi:10.1001/jama.1991.03460040065031
   PubMed Web of Science ®Google Scholar
• Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006;144(12):884–893. doi:10.7326/0003-4819-144-12-200606200-00005
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005. doi:10.1056/NEJMoa050461
   Web of Science ®Google Scholar
• Bangalore S, Messerli FH, Wun CC, et al. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) trial. Eur Heart J. 2010;31(23):2897–2908. doi:10.1093/eurheartj/ehq328
   PubMed Web of Science ®Google Scholar
• McEvoy JW, Chen Y, Rawlings A, et al. Diastolic blood pressure, subclinical myocardial damage, and cardiac events: implications for blood pressure control. J Am Coll Cardiol. 2016;68(16):1713–1722. doi:10.1016/j.jacc.2016.07.754
   PubMed Web of Science ®Google Scholar
• Vidal-Petiot E, Ford I, Greenlaw N, et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet Lond Engl. 2016;388(10056):2142–2152. doi:10.1016/S0140-6736(16)31326-5
   PubMed Web of Science ®Google Scholar
• Tsujimoto T, Kajio H. Low diastolic blood pressure and adverse outcomes in heart failure with preserved ejection fraction. Int J Cardiol. 2018;263:69–74. doi:10.1016/j.ijcard.2018.04.031
   Web of Science ®Google Scholar
• Flint AC, Conell C, Ren X, et al. Effect of systolic and diastolic blood pressure on cardiovascular outcomes. N Engl J Med. 2019;381(3):243–251. doi:10.1056/NEJMoa1803180
   PubMed Web of Science ®Google Scholar
• Böhm M, Ferreira JP, Mahfoud F, et al. Myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction: insights from the EPHESUS trial. Eur Heart J. 2020;41(17):1673–1683. doi:10.1093/eurheartj/ehaa132
   PubMed Web of Science ®Google Scholar
• Liew CH, McEvoy JW. The diastolic blood pressure J-curve remains an observational research phenomenon that has not yet been proven as causal and should not be used to make invasive treatment decisions. Eur Heart J. 2020;41(44):4284–4285. doi:10.1093/eurheartj/ehaa627
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet Lond Engl. 1998;351(9118):1755–1762. doi:10.1016/s0140-6736(98)04311-6
   PubMed Web of Science ®Google Scholar
• Beddhu S, Chertow GM, Cheung AK, et al. Influence of baseline diastolic blood pressure on effects of intensive compared to standard blood pressure control. Circulation. 2018;137(2):134–143. doi:10.1161/CIRCULATIONAHA.117.030848
   PubMed Web of Science ®Google Scholar
• ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–1574. doi:10.1056/NEJMoa1001282
   PubMed Web of Science ®Google Scholar
• Li J, Somers VK, Gao X, et al. Evaluation of optimal diastolic blood pressure range among adults with treated systolic blood pressure less than 130 mm Hg. JAMA Netw Open. 2021;4(2):e2037554. doi:10.1001/jamanetworkopen.2020.37554
   Web of Science ®Google Scholar
• Liu L, Mancia G. Termination of the ESH-CHL-SHOT trial. J Hypertens. 2020;38(12):2542–2543. doi:10.1097/HJH.0000000000002660
   Web of Science ®Google Scholar
• Kang YY, Wang JG. The J-curve phenomenon in hypertension. Pulse. 2016;4(1):49–60. doi:10.1159/000446922
   PubMedGoogle Scholar
• Harrison DG, Florentine MS, Brooks LA, Cooper SM, Marcus ML. The effect of hypertension and left ventricular hypertrophy on the lower range of coronary autoregulation. Circulation. 1988;77(5):1108–1115. doi:10.1161/01.CIR.77.5.1108
   Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H. coll. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008. doi:10.1056/NEJMoa0801317
   Web of Science ®Google Scholar
• Mancia G, Schumacher H, Redon J, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the ongoing telmisartan alone and in combination with ramipril global endpoint trial (ONTARGET). Circulation. 2011;124(16):1727–1736. doi:10.1161/CIRCULATIONAHA.110.008870
   PubMed Web of Science ®Google Scholar
• Park JH, Ovbiagele B. Post-stroke diastolic blood pressure and risk of recurrent vascular events. Eur J Neurol. 2017;24(11):1416–1423. doi:10.1111/ene.13411
   Web of Science ®Google Scholar
• Franklin SS, Lopez VA, Wong ND, et al. Single versus combined blood pressure components and risk for cardiovascular disease. Circulation. 2009;119(2):243–250. doi:10.1161/CIRCULATIONAHA.108.797936
   Web of Science ®Google Scholar
• Stefanie L, En TL, Panniyammakal J, Linsay M, Dominiczak Anna F, Sandosh P. Diastolic blood pressure J-curve phenomenon in a tertiary-care hypertension clinic. Hypertension. 2019;74(4):767–775. doi:10.1161/HYPERTENSIONAHA.119.12787
   Web of Science ®Google Scholar
• Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601. doi:10.1136/bmj.k601
   PubMed Web of Science ®Google Scholar
• Smith GD, Ebrahim S, Lip S, et al. “Mendelian randomization”: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1–22. doi:10.1093/ije/dyg070
   PubMed Web of Science ®Google Scholar
• Arvanitis M, Qi G, Bhatt DL, et al. Linear and nonlinear Mendelian randomization analyses of the association between diastolic blood pressure and cardiovascular events: the J-curve revisited. Circulation. 2021;143(9):895–906. doi:10.1161/CIRCULATIONAHA.120.049819
   PubMed Web of Science ®Google Scholar
• Malik R, Georgakis MK, Vujkovic M, et al. Relationship between blood pressure and incident cardiovascular disease: linear and nonlinear Mendelian randomization analyses. Hypertens Dallas Tex. 2021;77(6):2004–2013. doi:10.1161/HYPERTENSIONAHA.120.16534
   Web of Science ®Google Scholar